Anti-Human TNF alpha Recombinant Antibody Fab Fragment (Certolizumab Pegol) (CAT#: TAB-034-F(E))

Recombinant antibody Fragment Fab to TNF alpha. Certolizumab pegol is a monoclonal antibody directed against tumor necrosis factor alpha. More precisely, it is a PEGylated Fab' fragment of a humanized TNF inhibitor monoclonal antibody. Polyethylene glycol does not cross the placenta, so it should be safe in pregnancy.

Specific Inquiry Online Inquiry
  • Size:
  • Conjugation:
  • Endotoxin:
  • Purity:
  • Fc Engineering:
  • Published Data
  • Gene Expression
  • Datasheet
  • MSDS
  • COA
Activ

Figure 1 Efficacy variables in the certolizumab pegol (CZP) intention-to-treat (ITT) (n = 492) and week-24 CZP completer populations (n = 342).

Figure 1 Efficacy variables in the certolizumab pegol (CZP) intention-to-treat (ITT) (n = 492) and week-24 CZP completer populations (n = 342).

a Mean disease activity score in 28 joints (erythrocyte sedimentation rate) (DAS28(ESR)). b Mean health assessment questionnaire-disability index (HAQ-DI). c American College of Rheumatologists (ACR)20 response. d ACR50 and ACR70 responses. For patients who withdrew at week 16, observed data from the week-12 visit was also included in the week-24 data (start of open-label extension). MMRM mixed model repeated measures, NRI non-responder imputation.

Smolen, J. S., van Vollenhoven, R., Kavanaugh, A., Strand, V., Vencovsky, J., Schiff, M.,... & Carter, D. (2015). Certolizumab pegol plus methotrexate 5-year results from the rheumatoid arthritis prevention of structural damage (RAPID) 2 randomized controlled trial and long-term extension in rheumatoid arthritis patients. Arthritis research & therapy, 17(1), 245.

Activ

Figure 2 Efficacy variables in patients following dose reduction from certolizumab pegol (CZP) 400 mg every 2 weeks (Q2W) to CZP 200 mg Q2W (n = 369).

Figure 2 Efficacy variables in patients following dose reduction from certolizumab pegol (CZP) 400 mg every 2 weeks (Q2W) to CZP 200 mg Q2W (n = 369).

a Mean disease activity score in 8 joints (erythrocyte sedimentation rate) (DAS28(ESR)). bAmerican College of Rheumatology (ACR)20 response rates. c ACR50 and ACR70 response rates. This analysis is presented as weeks following dose-reduction visit (Week 0 is defined as the final efficacy assessment visit where a patient received the CZP 400 mg dose).

Smolen, J. S., van Vollenhoven, R., Kavanaugh, A., Strand, V., Vencovsky, J., Schiff, M.,... & Carter, D. (2015). Certolizumab pegol plus methotrexate 5-year results from the rheumatoid arthritis prevention of structural damage (RAPID) 2 randomized controlled trial and long-term extension in rheumatoid arthritis patients. Arthritis research & therapy, 17(1), 245.

Inhib

Figure 3 Effect of CZP in patients with and without prior TNF inhibitor exposure at week 24 in terms of ACR response and the kinetics of ACR response.

Figure 3 Effect of CZP in patients with and without prior TNF inhibitor exposure at week 24 in terms of ACR response and the kinetics of ACR response.

CZP, Certolizumab pegol; Q2W, every 2 weeks; Q4W, every 4 weeks; PBO, placebo; TNF, tumour necrosis factor. (A) Percentages of patients with and without prior TNF inhibitor exposure achieving a response according to the American College of Rheumatology Criteria for 20% improvement (ACR20), 50% improvement (ACR50), and 70% improvement (ACR70) at week 24, by treatment group. (B) Percentages of patients with prior TNF inhibitor exposure achieving an ACR20, ACR50, and ACR70 response over time, by treatment group. (C) Percentages of patients without prior TNF inhibitor exposure achieving an ACR20, ACR50 and ACR70 response over time, by treatment group; *p<0.001; †p<0.05 versus placebo.

Mease, P. J., Fleischmann, R., Deodhar, A. A., Wollenhaupt, J., Khraishi, M., Kielar, D.,... & Van Der Heijde, D. (2014). Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA). Annals of the rheumatic diseases, 73(1), 48-55.

FuncS

Figure 4 Emotional Function and Systemic Symptoms were the domains that patients reported as being most improved by certolizumab pegol treatment.

Figure 4 Emotional Function and Systemic Symptoms were the domains that patients reported as being most improved by certolizumab pegol treatment.

Mean change from baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) domain scores during 12 weeks subcutaneous treatment with either certolizumab pegol or placebo in patients with moderate-to-severe Crohn's disease (intent-to-treat population); least-squares means (adjusted for stratum, pooled country, and baseline score): a Bowel Symptoms domain, b Systemic Symptoms domain, c Emotional Function domain, and d Social Function domain.

Rutgeerts, P., Schreiber, S., Feagan, B., Keininger, D. L., O’Neil, L., & Fedorak, R. N. (2008). Certolizumab pegol, a monthly subcutaneously administered Fc-free anti-TNFα, improves health-related quality of life in patients with moderate to severe Crohn’s disease. International journal of colorectal disease, 23(3), 289-296.


Specifications

  • Immunogen
  • The details of the immunogen for this antibody are not available.
  • Host Species
  • Mouse
  • Derivation
  • Humanized (from mouse)
  • Type
  • Fab'
  • Specificity
  • Tested positive against native human antigen.
  • Species Reactivity
  • Human
  • Applications
  • ELISA, FC, IP, FuncS, IF, Neut, IHC, Activ, Inhib
  • Trade name
  • cimzia
  • CAS
  • 428863-50-7
  • Generic Name
  • Certolizumab pegol
  • ATC Code
  • L04AB05
  • ChEMBL
  • CHEMBL1201831
  • MW
  • 47.75 kDa
  • Related Disease
  • Psoriatic arthritis (PSA)

Product Property

  • Purity
  • >95.0% as determined by analysis by SDS-PAGE.
  • Storage
  • Store the antibody (in aliquots) at -20°C. Avoid repeated freezing and thawing of samples.

Applications

  • Application Notes
  • The TNF antibody has been reported in applications of ELISA, FC, IP, FuncS, IF, Neut, IHC, Activ, Inhib.

Target

  • Alternative Names
  • Certolizumab pegol;cimzia;428863-50-7;CDP870;PHA-738144;TNF;tumor necrosis factor;TNFA, tumor necrosis factor (TNF superfamily, member 2);DIF;TNF superfamily;member 2;TNF alpha;TNFSF2;TNF-a;cachectin;APC1 protein;TNF, monocyte-derived;TNF, macrophage-deri

Related Resources

  • Biosimilar Overview
  • Related Diseases
  • Related Signaling Pathways
Please refer to Certolizumab Pegol Overview to learn more about the mechanism of action, clinical projects, and approved drugs of Certolizumab Pegol.

Product Notes

This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:

• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production

See more details about Hi-Affi™ recombinant antibody benefits.

Downloads

Download resources about recombinant antibody development and antibody engineering to boost your research.

See other products for "TNF"

Chimeric Antibody

CAT Product Name Application Type
TAB-006 Anti-Human TNF Recombinant Antibody (Infliximab) IF, IP, Neut, FuncS, ELISA, FC, WB IgG1 - kappa
TAB-148CQ Anti-Human TNF Recombinant Antibody ELISA Chimeric antibody (mouse/human)
TAB-402CQ Human Anti-TNF Recombinant Antibody (TAB-402CQ) ELISA Chimeric (mouse/human) IgG
TAB-148CQ-F(E) Anti-Human TNF Recombinant Antibody Fab Fragment ELISA Chimeric antibody (mouse/human)
TAB-402CQ-F(E) Human Anti-TNF Recombinant Antibody; Fab Fragment (TAB-402CQ-F(E)) ELISA Chimeric (mouse/human) Fab

Rat Antibody

CAT Product Name Application Type
TAB-623CL Bovine Anti-TNF Recombinant Antibody (TAB-623CL) Neut Bovine IgG

Single-domain Antibody

Non-hyper Galactosylated

CAT Product Name Application Type
Gly-083LC-1 Recombinant Anti-Human TNF Antibody (Fc glycosylation/Non-hyper galactosylated) ELISA, FC Human antibody

Sialylated IgG Glycan

CAT Product Name Application Type
Gly-085LC-1 Recombinant Anti-Human TNF Antibody (Fc glycosylation/Sialylated) ELISA, FC Human antibody
Gly-163LC-1 Recombinant Anti-Human TNF Antibody (Fc glycosylation/Sialylated) ELISA Chimeric antibody (mouse/human)

Chicken IgY Antibody

CAT Product Name Application Type
BRD-0609MZ Chicken Anti-Tumor Necrosis Factor-α Polyclonal IgY Indirect ELISA, WB Chicken antibody

Blocking Antibody

CAT Product Name Application Type
NEUT-2057CQ Rat Anti-Tnf Recombinant Antibody (clone XT3) Block, ELISA, IHC, WB Rat IgG1
NEUT-2070CQ Mouse Anti-TNF Recombinant Antibody (clone 4F4) Block, ELISA, ICC, IF, IHC, WB Mouse IgG1
NEUT-2071CQ Rabbit Anti-TNF Recombinant Antibody (clone 6E10) Block, ELISA, IHC, WB Rabbit IgG1
NEUT-2082CQ Mouse Anti-TNF Recombinant Antibody (clone B-C7) Block Mouse IgG1

Neutralizing Antibody

ADCC Enhanced Antibody

CAT Product Name Application Type
AFC-TAB-768 Afuco™ Anti-TNF ADCC Recombinant Antibody (Nerelimomab), ADCC Enhanced FuncS, IF, Neut, ELISA, FC, IP ADCC enhanced antibody
AFC-TAB-006 Afuco™ Anti-TNF ADCC Recombinant Antibody (Infliximab), ADCC Enhanced IF, IP, Neut, FuncS, ELISA, FC ADCC enhanced antibody
AFC-TAB-010 Afuco™ Anti-TNF ADCC Recombinant Antibody (AFC-TAB-010), ADCC Enhanced FC, IP, ELISA, Neut, FuncS ADCC enhanced antibody

Submit a review or a question
There are currently no Customer reviews or questions for TAB-034-F(E). Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.

For Research Use Only. Not For Clinical Use.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Send Inquiry

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

  • 0
  • 0
Cart
    Go to compare

    Go to compare